ArticleFrontiers in plant science2018
Generation of Transgene-Free Maize Male Sterile Lines Using the CRISPR/Cas9 System.
Article in Frontiers in plant science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- A class II 5-enolpyruvylshikimate-3-phosphate synthase fromaBIOTECH · 2026Article
- Beyond GMOs: transgene-free gene-edited crops for global food security.Frontiers in plant science · 2026Review
- An accelerated transgene-free genome editing system using microparticle bombardment of sorghum immature embryos.aBIOTECH · 2025Article
- Genome editing in maize and sorghum: A comprehensive review of CRISPR/Cas9 and emerging technologies.The plant genome · 2025Review
- Application of genome editing in plant reproductive biology: recent advances and challenges.Plant reproduction · 2024Review
- OptimizingPlants (Basel, Switzerland) · 2024Review
- CRISPR/Cas genome editing in plants: mechanisms, applications, and overcoming bottlenecks.Functional & integrative genomics · 2024Review
- CRISPR/Cas Technology Revolutionizes Crop Breeding.Plants (Basel, Switzerland) · 2023Review
- Current insights and advances into plant male sterility: new precision breeding technology based on genome editing applications.Frontiers in plant science · 2023Review
- CRISPR/Cas genome editing system and its application in potato.Frontiers in genetics · 2023Review
- Development of new mutant alleles and markers forFrontiers in plant science · 2023Article
- CRISPR/Cas9-mediated homology donor repair base editing confers glyphosate resistance to rice (Frontiers in plant science · 2023Article
- Article
- CRISPR/Cas9 Technology and Its Utility for Crop Improvement.International journal of molecular sciences · 2022Review
- Application of CRISPR/CasΦ2 System for Genome Editing in Plants.International journal of molecular sciences · 2022Article
- Advance of Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 System and Its Application in Crop Improvement.Frontiers in plant science · 2022Review
- CRISPR/Cas9 and Nanotechnology Pertinence in Agricultural Crop Refinement.Frontiers in plant science · 2022Review
- CRISPR-Cas technology opens a new era for the creation of novel maize germplasms.Frontiers in plant science · 2022Review
- Homology-based identification of candidate genes for male sterility editing in upland cotton (Frontiers in plant science · 2022Review
- A CRISPR way for accelerating cereal crop improvement: Progress and challenges.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male sterility (MS) provides a useful breeding tool to harness hybrid vigor for hybrid seed production. It is necessary to generate new male sterile mutant lines for the development of hybrid seed production technology. The CRISPR/Cas9 technology is well suited for targeting genomes to generate male sterile mutants. In this study, we artificially synthesized
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.